Shanghai, September 7, 2022 - Luye Pharma Group announced today that BA1106, a human anti-CD25 monoclonal antibody developed by its subsidiary Boan Biotech, has been approved for clinical trials by th...
Luye Pharma Group announced on July 14 that its subsidiary Boan Biotech has started a Phase III clinical trial, which is a comparative clinical efficacy and safety study, for Dulaglutide Injection (BA...
February 25, 2022, Shanghai —Boan Biotech today announced that Boyounuo® (Bevacizumab Injection), an anticancer biologic, has been approved by China’s National Medical Products Administration (...
Luye Pharma Group today announced that the first patient has been enrolled in a Phase I clinical trial for BA1105, an investigational anti-Claudin18.2 antibody developed by its subsidiary Boan Biotech...
Shanghai, December 14, 2021—Luye Pharma Group announced that the clinical trial application for BA1201, an anti-PD-L1/TGF-β bispecific antibody developed by its subsidiary Boan Biotech, has been...
The findings about BA1106, a fully human monoclonal anti-CD25 antibody developed by Boan Biotech, a subsidiary of Luye Pharma Group, were published in Scientific Reports, which is a journal of the Nat...
Boan Biotech, a subsidiary of Luye Pharma Group, announced today that it has signed a Memorandum of Understanding with Merck, a world-leading science and technology company, under which the two partie...
Clinical trials of the drug in Europe and the U.S. are making good progressOctober 13, 2021, Shanghai -- Luye Pharma Group announced that the marketing authorization application for the Denosumab Inje...
Luye Pharma Group today announced that BA1105, a novel antibody developed by its subsidiary Boan Biotech, has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Prod...
September 27, 2021, Shanghai, China – Luye Pharma Group today announced that Dulaglutide Injection (BA5101) developed in-house by Boan Biotech, a subsidiary of the Group, has obtained approval f...
